We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
- Recent CBAY Stock Price: $9.17
- Yearly Gain for CBAY stock: 405.26%
- Market Cap for CBAY stock: $936.13M
- P/E Ratio for CBAY stock: -8.103
Will CBAY's stock price go up? Is there an accurate CBAY stock forecast available?
TipRanks.com reports that CymaBay Therapeutics currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $14.22. The target pricing ranges from a high CBAY forecast of $19.00 down to a low forecast of $12.00. CymaBay Therapeutics (CBAY)’s last closing stock price was $9.17 which would put the average price target at 62.47% upside.
In addition, TradingView issued a Sell rating for CBAY stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CBAY stock.
Other analysts covering CBAY include:
- Jay Olson of Oppenheimer issued a Buy rating with the price target of $ 16 on 1 day ago
- Kristen Kluska of Cantor Fitzgerald issued a Buy rating with the price target of $ 15 on 1 day ago
- Sean Kim PhD of JonesTrading issued a Buy rating with the price target of $ 13 on 1 day ago
- Patrick Dolezal of LifeSci Capital issued a Buy rating with the price target of $ 15 on 1 day ago
If you are wondering if CBAY is a good stock to buy, here are 3rd party ratings for CBAY stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 49% (124 out of 251)
What is the sentiment on the street regarding CymaBay Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for CBAY stock: Very Bullish
- Blogger Consensus for CBAY stock: Bullish
- Media Buzz for CBAY stock: Medium
- Insider Signal for CBAY stock: Negative
- Investor Sentiment for CBAY stock: Very Positive
- Hedge Fund signal for CBAY stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on CBAY stock including scouring the social networks like CBAY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CBAY stock chart >>
Summary: Disc Medicine Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases. Disc Medicine Inc., formerly known as Gemini Therapeutics Inc., is based in WAYLAND, Mass.
- Recent IRON Stock Price: $34.05
- Yearly Gain for IRON stock: 138.50%
- Market Cap for IRON stock: $661.10M
- P/E Ratio for IRON stock: -0.781
Will IRON's stock price go up? Is there an accurate IRON stock forecast available?
TipRanks.com reports that Disc Medicine currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $38.29. The target pricing ranges from a high IRON forecast of $45.00 down to a low forecast of $36.00. Disc Medicine (IRON)’s last closing stock price was $34.05 which would put the average price target at 17.86% upside.
In addition, TradingView issued a Buy rating for IRON stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IRON stock.
Other analysts covering IRON include:
- Thomas Smith of SVB Securities issued a Buy rating with the price target of $ 36 on 2 days ago
- Evan Seigerman of BMO Capital issued a Buy rating with the price target of $ 40 on 2 days ago
- Rami Katkhuda of LifeSci Capital issued a Buy rating with the price target of $ 37 on 2 days ago
- Benjamin Burnett of Stifel Nicolaus issued a Buy rating with the price target of $ 40 on 2 days ago
If you are wondering if IRON is a good stock to buy, here are 3rd party ratings for IRON stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 46% (115 out of 251)
What is the sentiment on the street regarding Disc Medicine? (Current ratings compiled by TipRanks.com)
- News Sentiment for IRON stock: Very Bullish
- Blogger Consensus for IRON stock: Bullish
- Media Buzz for IRON stock: Very Low
- Insider Signal for IRON stock: ―
- Investor Sentiment for IRON stock: ―
- Hedge Fund signal for IRON stock: No Signal
The stock market is extremely volatile, and you need to do your own research on IRON stock including scouring the social networks like IRON StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IRON stock chart >>
Summary: IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences Inc. is based in Mountain View, California.
- Recent IGMS Stock Price: $11.90
- Yearly Gain for IGMS stock: -25.96%
- Market Cap for IGMS stock: $552.04M
- P/E Ratio for IGMS stock: -2.247
Will IGMS's stock price go up? Is there an accurate IGMS stock forecast available?
TipRanks.com reports that IGM Biosciences currently has 9 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $30.78. The target pricing ranges from a high IGMS forecast of $49.00 down to a low forecast of $20.00. IGM Biosciences (IGMS)’s last closing stock price was $11.90 which would put the average price target at 155.88% upside.
In addition, TradingView issued a Sell rating for IGMS stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on IGMS stock.
Other analysts covering IGMS include:
- Michael Schmidt of Guggenheim issued a Buy rating with the price target of $ 38 on 2 days ago
- Brian Abrahams of RBC Capital issued a Hold rating with the price target of $ 17 on 2 days ago
- Geoff Meacham of Bank of America Securities issued a Buy rating with the price target of $ 29 on 2 days ago
- Robert Driscoll of Wedbush issued a Buy rating with the price target of $ 37 on 2 days ago
If you are wondering if IGMS is a good stock to buy, here are 3rd party ratings for IGMS stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 46% (115 out of 251)
What is the sentiment on the street regarding IGM Biosciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for IGMS stock: Very Bullish
- Blogger Consensus for IGMS stock: Bullish
- Media Buzz for IGMS stock: Very Low
- Insider Signal for IGMS stock: Very Negative
- Investor Sentiment for IGMS stock: ―
- Hedge Fund signal for IGMS stock: Neutral
The stock market is extremely volatile, and you need to do your own research on IGMS stock including scouring the social networks like IGMS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IGMS stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
